Last reviewed · How we verify
NCT05594758
Named Patient Program for Olverembatinib (HQP1351)
trial testing Olverembatinib. Available.
Quick facts
| Lead sponsor | Ascentage Pharma Group Inc. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Olverembatinib — full drug profile →
Sponsor
Ascentage Pharma Group Inc. — full company profile →
Who can join
Adults 18 to 99, any sex. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This program will allow eligible patients access to Ascentage Pharma's novel drug candidate Olverembatinib (approved in China) on a named patient basis in over 100 countries ( with the exception of the USA and China) and regions where the drug is not available.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancements and Future Prospects in Molecular Targeted and siRNA Therapies for Chronic Myeloid Leukemia
Vysochinskaya V, Dovbysh O, Gorshkov A, Brodskaia A, et al · · 2024
Verify or expand the search:
- PubMed search for NCT05594758
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Olverembatinib
Trials testing the same drug.
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07493161 — Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL · NA · not yet recruiting
- NCT06757855 — Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML · Phase 1, PHASE2 · recruiting
- NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
- NCT06401603 — A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Ph · Phase 1 · recruiting
Other Ascentage Pharma Group Inc. trials
Trials by the same sponsor.
- NCT07282093 — Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment · Phase 1 · recruiting
- NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
- NCT06389292 — A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia · Phase 3 · recruiting
- NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
- NCT06051409 — A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05594758 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ascentage Pharma Group Inc.
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594758.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing